Tekmira to Present at the 16th Annual BIO CEO & Investor Conference

| Source: Arbutus Biopharma Corporation

VANCOUVER, B.C., Feb. 5, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that Dr. Mark Murray, President and CEO of Tekmira, will provide a corporate overview on Tuesday, February 11, 2014 at 8:30 am ET at the 16 Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York City.

Webcast Information

A live webcast of this presentation can be accessed through the Investor section of Tekmira's website at www.tekmirapharm.com. A replay of webcast will be available on the Tekmira website following the event.

About Tekmira

Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM) is a biopharmaceutical company focused on advancing novel RNA interference (RNAi) therapeutics and providing its leading lipid nanoparticle (LNP) delivery technology to its partners. Tekmira has been working in the field of nucleic acid delivery for over a decade and has broad intellectual property covering its delivery technology. Further information about Tekmira can be found at www.tekmirapharm.com.

Jodi Regts
Director, Investor Relations
Phone: 604-419-3234

David Ryan
Longview Communications Inc.
Phone: 416-649-8007